This technology is a set of markers for terminal erythroid differentiation (TED) for prognosis of myelodysplastic syndrome (MDS) before progression to acute myeloid leukemia (AML).
In patients with MDS, accurate prediction of progression to AML is critical for determining the appropriate course of treatment and improving patient survival. Current prognostic tools are technically complex and rely on observer skill, which often results in low accuracy predictions. Additional testing tools and prognostic markers for progression to AML are needed to increase the accuracy of these predictions.
This technology is a multi-gene prognostic classifier that accurately predicts progression of MDS to AML using transcriptomic analysis of bone marrow samples. The classifier uses transcriptomic signatures and TED to accurately predict fast progression (<2 years) to AML, which is critical for determining the appropriate course of treatment for patients. The analysis can be done using standard biomedical assays, which reduces the observer bias of current prognostic tools. This technology can be further utilized to understand the pathology of disease progression and may lead to the identification of therapeutic targets.
This technology has been validated in human patient samples (n=221).
IR CU17287, CU18296
Licensing Contact: Joan Martinez
